- Home
- PAYO vs VERA Comparison
PAYO vs VERA Comparison
Compare PAYO & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAYO | VERA |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.5B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PAYO | VERA |
|---|---|---|
| Price | $5.71 | $53.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $9.21 | ★ $76.60 |
| AVG Volume (30 Days) | ★ 3.0M | 1.8M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $1,039,820,000.00 | N/A |
| Revenue This Year | $11.18 | N/A |
| Revenue Next Year | $7.45 | N/A |
| P/E Ratio | $31.29 | ★ N/A |
| Revenue Growth | ★ 10.58 | N/A |
| 52 Week Low | $4.92 | $18.53 |
| 52 Week High | $11.19 | $56.05 |
Technical Indicators
Market Signals| Indicator | PAYO | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 48.44 | 80.23 |
| Support Level | $5.46 | $47.22 |
| Resistance Level | $5.94 | $56.05 |
| Average True Range (ATR) | 0.18 | 2.89 |
| MACD | -0.01 | 0.39 |
| Stochastic Oscillator | 42.15 | 85.61 |
Price Performance
Historical ComparisonAbout PAYO Payoneer Global Inc.
Payoneer Global Inc is a financial technology company purpose-built to enable the world's small and medium-sized businesses (SMB(s)) to grow and operate their businesses around the world by reliably and securely connecting them to the digital economy. The company started to empower commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.